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Conventional cytostatic cancer treatments are rarely
curative. New therapeutic strategies are more promising
by targeting the tumor microenvironment, inhibiting
angiogenesis and antagonizing the immunosuppressive
activity of established tumors. Along these lines, plants
provide a broad spectrum of potential drugs for cancer
therapy, such as betulin, a pentacyclic triterpene of the
birch tree representing the reduced congener of betuli-
nic acid. An anticancer activity of betulinic acid has
been shown already and was linked to its ability to
directly trigger mitochondrial membrane permeabiliza-
tion, a central event in the apoptotic process. In contrast
to the potent cytostatic action towards different tumor
cell lines, non-neoplastic cells and normal tissue remain
relatively resistant.
This study aimed to investigate the antitumor activity
on melanoma cells and the immune modulating effect on
dendritic cells and T cells of the phytocompound betulin
to improve the melanoma immunotherapy by this adju-
vant. By means of diverse proliferation assays as well as
nuclear DAPI staining we could confirm that betulin
decreased the proliferation rate of both the highly meta-
static B16F10 and the low metastatic B164A5 melanoma
cell lines. In addition, annexin V/7-aminoactinomycin D
staining revealed that betulin induced a higher rate of
apoptosis in melanoma cells as compared to primary
bone marrow derived dendritic cells (BMDCs) of C57BL/
6 mice. Furthermore, as evaluated by co-incubation
assays and ELISA we found that betulin significantly sti-
mulated the Toll-like-receptor-4-dependent IL-12p70
production of murine BMDCs (n = 3, p ≤ 0.01). We
could further show that this increased secretion of IL-
12p70 protein was due to an increased IL-12p35 mRNA
expression, while the mRNA level of the IL-12p40
subunit remained unchanged (n = 10, p ≤ 0.001). Inter-
estingly, other cytokines like IL-6, IL-10 or IL-23 were
also not affected by treatment with betulin. Subsequent
ex vivo experiments utilizing transgenic spleen cells
revealed that the betulin-enhanced activation of dendritic
cells is transmitted to an increased, antigen-specific
T cell stimulation as demonstrated by an induction of
IL-2 and interferon-gamma in ELISA and ELISPOT ana-
lysis (n = 3, p ≤ 0.5). A next step would be to load dendri-
tic cells with specific melanoma antigens to receive a
directed immune response against the tumor tissue and
confirm these results in vivo.
In summary, cytostatic agents like betulin that simulta-
neously exhibit immune stimulatory activity hold great
promise as a novel approach for an integrated cancer
therapy.
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